Patient Experience Program
This link isn’t valid
Please contact your Tenpoint representative for a new link. If you’ve used the survey before, try reopening the original link from your program email.
Please contact your Tenpoint representative for a new link. If you’ve used the survey before, try reopening the original link from your program email.
Tap for safety information
YUVEZZI is indicated for the treatment of presbyopia in adults.
YUVEZZI is contraindicated in patients with known hypersensitivity to the active ingredients or to any of the excipients.
Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). In addition, patients may experience temporary dim or dark vision with miotics. Advise patients to exercise caution in night driving and other hazardous activities in poor illumination.
Rare cases of retinal tear and detachment have been reported with miotics. Individuals with pre-existing retinal disease are at increased risk. Examination of the retina is advised in all patients prior to the initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.
YUVEZZI is not recommended to be used when iritis is present.
Avoid touching the vial to the eye, eyelids, or to any other surface.
YUVEZZI may potentiate syndromes associated with vascular insufficiency.
The most common adverse reactions were eye pain upon instillation, visual impairment, eye irritation upon instillation, and headache. The majority of adverse events were mild, transient, and self-resolving.
To report SUSPECTED ADVERSE REACTIONS, contact Visus Therapeutics, Inc., at 1-888-735-0821 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
